LIFE SCIENCE INVESTMENTS
A novel investment platform developed by the FreeMind Group
Developed by the FreeMind Group
A novel and effective investment vehicle aimed at bridging the infamous biotech startup “valley of death” and generating high returns, while furthering the development of medical solutions to a wide variety of unmet needs.
Based on FreeMind’s data set, empirically shown to yield a high return on investment
The NIH reviews ~40,000 applications every year, of which ~5,000 are industry oriented submissions. Each application is peer reviewed by a select group of specialized researchers, senior academics, and experienced industry leaders. Reviewers provide a numerical value for five discrete review criteria summed as a single score, as well as a detailed explanation of the strengths and weaknesses of each parameter. The result is a quantitative, uniform, and comparable sliding scale of application submissions from the most worthy to the least.
Over the years, FreeMind has acquired a great deal of perspective as it relates to industry needs, expectations, and keys to success. Combining FreeMind’s “soft” company-specific knowledge, together with an intimate understanding of the multifaceted NIH review and scoring system, we developed a novel, yet simple, investment model. Supported by studies conducted by top tier economists showing economic and financial benefit stemming from the NIH scoring system, we adjusted the NIH formula to reflect additional pertinent industry and business characteristics.
We tested our model under various investment strategies on a data set from FreeMind’s portfolio companies (2013-2016) and found the model to be predictive of substantial return on potential investment, thus providing further validity to our empirical findings. We are currently seeking investment opportunities stemming from FreeMind’s client base. Clients who score well and adhere to additional investment criteria serve as deal flow for the FreeMind Group Investment Arm.